Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Feb;48(2):300060520903666.
doi: 10.1177/0300060520903666.

Bone mineral density and its correlation with serum 25-hydroxyvitamin D levels in patients with hyperthyroidism

Haixia Liu  1 , Qihang Ma  1 , Xinli Han  2 , Wenwen Huang  1
Affiliations

Bone mineral density and its correlation with serum 25-hydroxyvitamin D levels in patients with hyperthyroidism

Haixia Liu et al. J Int Med Res. 2020 Feb.

Abstract

Objective: This study aimed to determine the association between 25-hydroxyvitamin D (25(OH)D) levels and bone mineral density (BMD) in patients with hyperthyroidism after undergoing treatment.

Methods: A total of 120 patients with hyperthyroidism were selected as participants. Methimazole tablets were provided to all of the participants, with an initial dose of 20 mg/day and a maintenance dose of 2.5 mg/day for 1 year. Blood calcium, phosphate, parathyroid hormone (PTH), and thyroid hormone levels were assayed using an automatic biochemical analyzer. Levels of 25(OH)D and bone alkaline phosphatase (ALP) in serum were determined by enzyme-linked immunosorbent assay. BMD was measured using dual energy X-ray absorptiometry.

Results: Serum phosphorus, PTH, and 25(OH)D levels in patients with hyperthyroidism were significantly higher, and bone ALP and 24-hour urinary calcium levels were significantly lower after treatment compared with before treatment. BMD in patients with hyperthyroidism was significantly improved after treatment. In logistic regression analysis of BMD-related risk factors, bone ALP, PTH, and 25(OH)D levels were risk factors of BMD.

Conclusion: Treatment for hyperthyroidism should be supplemented with vitamin D and calcium, which have important clinical significance for adjusting bone metabolism and delaying the process of osteoporosis.

Keywords: 25-hydroxyvitamin D; Hyperthyroidism; bone mineral density; calcium; parathyroid hormone; thyroid function.

PubMed Disclaimer

References

    1. Nagayama Y, McLachlan SM, Rapoport Bet al. Graves’ hyperthyroidism and the hygiene hypothesis in a mouse model. Endocrinology 2004; 145: 5075–5079. - PubMed
    1. Tsevis K, Trakakis E, Pergialiotis Vet al. The influence of thyroid disorders on bone density and biochemical markers of bone metabolism. Horm Mol Biol Clin Investig 2018; 35. doi: 10.1515/hmbci-2018-0039. - PubMed
    1. Ganji R, Moghbeli M, Sadeghi Ret al. Prevalence of osteoporosis and osteopenia in men and premenopausal women with celiac disease: a systematic review. Nutr J 2019; 18: 9. - PMC - PubMed
    1. Chang YF, Huang CF, Hwang JSet al. Fracture liaison services for osteoporosis in the Asia-Pacific region: current unmet needs and systematic literature review. Osteoporos Int 2018; 29: 779–792. - PubMed
    1. Yoon BH, Lee Y, Oh HJet al. Influence of thyroid-stimulating hormone suppression therapy on bone mineral density in patients with differentiated thyroid cancer: a meta-analysis. J Bone Metab 2019; 26: 51–60. - PMC - PubMed

MeSH terms